Navigation Links
BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
Date:5/15/2008

Presentation will be Web cast live

LAVAL, QC, May 15 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU, formerly known as Neurochem Inc.) announces today that on Monday, May 19, 2008, Dr. Francesco Bellini, BELLUS Health's Chairman, President and Chief Executive Officer will present BELLUS Health's strategy at the Rodman and Renshaw 5th Annual Global Healthcare Conference to be held at the Le Meridien Beach Plaza Hotel Monte Carlo, Monaco. The presentation will take place at 11:05 A.M. CEST (05:05 A.M. EDT).

The live Web cast of BELLUS Health's presentation (audio and visual) can be accessed at http://www.wsw.com/webcast/rrshq13/blus/. A replay of the presentation will begin three (3) hours after the actual presentation time, and will be available until May 26, 2008. Please access the Web cast approximately 15 minutes before the presentation is scheduled to begin.

About BELLUS Health

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.

To Contact BELLUS Health

For additional information on BELLUS Health and its programs, please call the Canada and United States toll-free number 1-877-680-4500 or visit the Web Site at http://www.bellushealth.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s (formerly known as Neurochem Inc.) control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of BELLUS Health Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health group and its business.

CONTACT: Lise Hebert, Ph.D., Vice President, Corporate Communications, (450) 680-4572, lhebert@bellushealth.com


'/>"/>
SOURCE BELLUS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. Penn study finds pro-death proteins required to regulate healthy immune function
4. UCLA researchers identify markers that may predict diabetes in still-healthy people
5. Air pollution linked to cardiovascular risk indices in healthy young adults
6. More proof needed of safety and quality of electronic personal health records
7. Health care incentive model offers collaborative approach
8. Loneliness is bad for your health
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Green Tea May Brew Up Healthier Skin
11. For Health Info, Women Often Turn to the Web
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, ... their training and leads programs. , In February, 2017, Empower Brokerage introduced their ... Performance Partners is designed to teach how to maximize their sales efforts, as ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through Social Media: ... journal chronicling the writer’s path toward true communion with God. “Finding Christ Through ... is the creation of published author Lea Michelle Johnson, a follower of Christ, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... “Vintage and ... a retired minister and college Bible teacher residing in North Carolina with his wife, ... who have blessed them with six grandchildren. David is also the author of “Shadow ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story ... fullest, as God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” ... passion for writing, especially about truth and human behavior. , Published by Christian Faith ...
(Date:3/23/2017)... ... ... A recent report from the National Council on Teacher Quality (NCTQ) advocates for ... on a review of GPA and SAT/ACT requirements at 221 institutions in 25 states, ... that this higher bar should be set by states, by the Council for the ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... ShangPharma, a leading life science ... development and discovery services, technology, and investment ... today the intent for a strategic corporate ... the Contract Research Organizations (CRO) and Contract ... entities include ChemPartner Shanghai, ChemPartner Fengxian, ChemPartner ...
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com ... has been growing rapidly as the global sales of Adcetris and ... growth in the antibody drug conjugates market is driven by large ... cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, ...
(Date:3/24/2017)... 24, 2017  Eli Lilly and Company (NYSE: ... invest $850 million in its U.S. operations in ... U.S. enterprise, including research laboratories, manufacturing sites, and ... driven by demand for Lilly products, as well ... development targeting cancer, pain, diabetes and other unmet ...
Breaking Medicine Technology: